Clinical TrialJul 13, 2026, 09:03 AM
Artelo Biosciences ART27.13 Shows Promise in Neuropathic Pain
AI Summary
Artelo Biosciences announced promising nonclinical study results for ART27.13, its proprietary cannabinoid receptor agonist, in treating neuropathic pain in cancer patients. The findings suggest ART27.13, currently in Phase 2 for cancer-related anorexia cachexia syndrome (CACS), may have broader utility in cancer supportive care. Researchers observed that ART27.13 reduced neuropathic pain-associated behaviors in models of paclitaxel-induced peripheral neuropathy. These new results complement interim Phase 2 CAReS study findings, which showed encouraging trends in body weight, lean body mass, and activity levels for CACS patients.
Key Highlights
- ART27.13 nonclinical studies showed reduced neuropathic pain in paclitaxel-treated animals.
- Neuropathic pain affects 60%-80% of patients receiving paclitaxel chemotherapy.
- Interim Phase 2 CAReS study showed ART27.13 improved body weight, lean body mass, and activity levels.
- ART27.13 demonstrated a favorable safety profile at doses up to 1300 µg/day in CAReS study.
- CACS affects up to 80% of patients with advanced malignancies.
- There are currently no FDA-approved treatments for CACS.
Price Impact
More from ARTL